Details of the Drug Combinations

General Information of This Drug (ID: DMDBX5F)

• Drug Name: Ivermectin (DMDBX5F)
• Synonyms: I 8898; Ivexterm (TN); MK-933; Mectizan (TN); Stromectol (TN)

Indication

Intestinal strongyloidiasis due to nematode parasite; ICD 11: 1F6B; Status: Approved [1]; Onchocerciasis; ICD 11: 1F6A; Status: Approved [2]; Strongyloidiasis; ICD 11: N.A.; Status: Approved [3]; Coronavirus Disease 2019 (COVID-19); ICD 11: 1D6Y; Status: Phase 2/3 [4]

• Therapeutic Class: Antiprotozoal Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

15 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Bifemelane + Ivermectin	DCA4M0N	Bifemelane	Hepatoblastoma (Cell Line: HB3)	[5]
Dihydroergotamine + Ivermectin	DC38QCG	Dihydroergotamine	DD2 (Cell Line: DD2)	[6]
Ivermectin + Lumefantrine	DCSDCSE	Lumefantrine	DD2 (Cell Line: DD2)	[6]
Ivermectin + Dactinomycin	DCK21TC	Dactinomycin	DD2 (Cell Line: DD2)	[6]
Ivermectin + Dactinomycin	DCGGINU	Dactinomycin	Hepatoblastoma (Cell Line: HB3)	[6]
Ivermectin + T-3.5	DC5RXX5	T-3.5	Hepatoblastoma (Cell Line: HB3)	[6]
Ivermectin + Artemether	DCQ2I9U	Artemether	DD2 (Cell Line: DD2)	[6]
Ivermectin + Dihydroergotamine	DCRSX37	Dihydroergotamine	DD2 (Cell Line: DD2)	[6]
Ivermectin + Thiolactomycin	DCNFEBC	Thiolactomycin	DD2 (Cell Line: DD2)	[6]
Ivermectin + MK-4815	DCGO26Z	MK-4815	DD2 (Cell Line: DD2)	[6]
Ivermectin + Pyronaridine	DCG2ZSG	Pyronaridine	Hepatoblastoma (Cell Line: HB3)	[6]
Ivermectin + Mefloquine	DCXF2SB	Mefloquine	DD2 (Cell Line: DD2)	[6]
Ivermectin + Atovaquone	DCK7N2I	Atovaquone	DD2 (Cell Line: DD2)	[6]
Sorafenib + Ivermectin	DCSWNWO	Sorafenib	DD2 (Cell Line: DD2)	[6]
ZM-447439 + Ivermectin	DCCY6CT	ZM-447439	DD2 (Cell Line: DD2)	[6]

16 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Diethylcarbamazine + Ivermectin	DCOEL2G	Diethylcarbamazine	Lymphatic Filariasis	[7]
Ethanol + Ivermectin	DC3VXH6	Ethanol	Alcohol Use Disorder	[8]
Ivermectin + Montelukast	DC2PVOE	Montelukast	Covid19	[9]
Diethylcarbamazine + Ivermectin	DCECRNA	Diethylcarbamazine	Lymphatic Filariasis	[10]
Ivermectin + Hydroxychloroquine	DC4A3GX	Hydroxychloroquine	Covid19	[11]
Ivermectin + Albendazole	DCKYM7E	Albendazole	Malaria	[12]
Ivermectin + Losartan	DCSX87U	Losartan	Cancer	[13]
Diethylcarbamazine + Ivermectin	DCU30FZ	Diethylcarbamazine	Lymphatic Filariasis	[14]
Ivermectin + Malathion	DCW6S9Y	Malathion	Scabies	[15]
Ivermectin + Hydroxychloroquine	DC37HGN	Hydroxychloroquine	Coronavirus Disease 2019 (COVID-19)	[16]
Metformin + Ivermectin	DCCBRXW	Metformin	Covid19	[17]
Nitazoxanide + Ivermectin	DC4D4U5	Nitazoxanide	Coronavirus Disease 2019 (COVID-19)	[18]
Nitazoxanide + Ivermectin	DCVPWKN	Nitazoxanide	Coronavirus Disease 2019 (COVID-19)	[19]
Doxycycline + Ivermectin	DCUPYZZ	Doxycycline	Covid19	[20]
Ivermectin + Azithromycin	DCCFALE	Azithromycin	Scabies	[21]
Ivermectin + Brimonidine	DCUUCHT	Brimonidine	Rosacea	[22]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2373).
• [2] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 202736
• [3] Ivermectin FDA Label
• [4] ClinicalTrials.gov (NCT04351347) The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment. U.S. National Institutes of Health.
• [5] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [6] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [7] ClinicalTrials.gov (NCT02974049) Lymphatic Filariasis (LF) in Ivory Coast
• [8] ClinicalTrials.gov (NCT02046200) Development of Ivermectin for Alcohol Use Disorders
• [9] ClinicalTrials.gov (NCT04714515) Montelukast - a Treatment Choice for COVID-19
• [10] ClinicalTrials.gov (NCT03664063) PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )
• [11] ClinicalTrials.gov (NCT04712279) The (HD)IVACOV Trial (The High-Dose IVermectin Against COVID-19 Trial)
• [12] ClinicalTrials.gov (NCT02509481) Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
• [13] ClinicalTrials.gov (NCT04447235) Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection
• [14] ClinicalTrials.gov (NCT04410406) Moxidectin for LF, Cote d'Ivoire (DOLF)
• [15] ClinicalTrials.gov (NCT03236168) Impact of Community Scabies Treatment on Head Lice Prevalence in the Solomon Islands
• [16] ClinicalTrials.gov (NCT04374019) Novel Agents for Treatment of High-risk COVID-19 Positive Patients. U.S. National Institutes of Health.
• [17] ClinicalTrials.gov (NCT04510194) COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
• [18] ClinicalTrials.gov (NCT04382846) Novel Regimens in COVID-19 Treatment. U.S. National Institutes of Health.
• [19] ClinicalTrials.gov (NCT04360356) Ivermectin and Nitazoxanide Combination Therapy for COVID-19. U.S. National Institutes of Health.
• [20] ClinicalTrials.gov (NCT04729140) An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization
• [21] ClinicalTrials.gov (NCT02775617) Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
• [22] ClinicalTrials.gov (NCT02616250) MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.